Cover Image

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and <i>O</i>-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling

Tramadol is a μ-opioid receptor agonist and a monoamine reuptake inhibitor. <i>O</i>-desmethyltramadol (M1), the major active metabolite of tramadol, is produced by CYP2D6. A physiologically-based pharmacokinetic model was developed to predict changes in time-concentration profi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hyeon-Cheol Jeong (Author), Soo Hyeon Bae (Author), Jung-Woo Bae (Author), Sooyeun Lee (Author), Anhye Kim (Author), Yoojeong Jang (Author), Kwang-Hee Shin (Author)
Format:	Book
Published:	MDPI AG, 2019-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Population pharmacokinetic analysis of tramadol and O-desmethyltramadol with genetic polymorphism of CYP2D6
by: Lee J, et al.
Published: (2019)

Pharmacokinetics, safety and tolerability of valbenazine in Korean CYP2D6 normal and intermediate metabolizers
by: Woo Kyung Chung, et al.
Published: (2023)

Prediction of the Drug-Drug Interaction Potential between Tegoprazan and Amoxicillin/Clarithromycin Using the Physiologically Based Pharmacokinetic and Pharmacodynamic Model
by: Zhuodu Wei, et al.
Published: (2023)

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with <i>N</i>-Dimethylnitrosamine-Induced Liver Cirrhosis
by: Sung Hun Bae, et al.
Published: (2022)

Population Pharmacokinetics of <i>Cis</i>-, <i>Trans</i>-, and Total Cefprozil in Healthy Male Koreans
by: Ji-Hun Jang, et al.
Published: (2019)

Physiologically based pharmacokinetic modeling to predict the pharmacokinetics of codeine in different CYP2D6 phenotypes
by: Yujie Yang, et al.
Published: (2024)

Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: a population pharmacokinetics analysis
by: Jing Ling, et al.
Published: (2024)

Effects of <i>CYP3A5</i> Genotype on Tacrolimus Pharmacokinetics and Graft-versus-Host Disease Incidence in Allogeneic Hematopoietic Stem Cell Transplantation
by: Daniel N. Marco, et al.
Published: (2024)

Variants in <i>COMT</i>, <i>CYP3A5</i>, <i>CYP2B6,</i> and <i>ABCG2</i> Alter Quetiapine Pharmacokinetics
by: Pablo Zubiaur, et al.
Published: (2021)

Population Pharmacokinetics of Primaquine in the Korean Population
by: Woo-Yul Lee, et al.
Published: (2021)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug-Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
by: Laura Maria Fuhr, et al.
Published: (2021)

Understanding inter-individual variability in pharmacokinetics/pharmacodynamics of aripiprazole in children with tic disorders: Individualized administration based on physiological development and CYP2D6 genotypes
by: Yingying Xin, et al.
Published: (2022)

Effect of co-administered inducer or inhibitor on omeprazole pharmacokinetics based on CYP2C19 genotype
by: Chiaki Kamiya, et al.
Published: (2019)

Phase I clinical trial of NH130 and the prediction of its pharmacokinetics using physiologically based pharmacokinetic modeling
by: Kun Zhang, et al.
Published: (2024)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
by: Takashi Ueno, et al.
Published: (2021)

An Investigational Study on the Role of <i>CYP2D6</i>, <i>CYP3A4</i> and <i>UGT</i>s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024)

Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intragastric pH Alterations
by: Hyeon-Cheol Jeong, et al.
Published: (2022)

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects
by: Jiang X, et al.
Published: (2023)

<i>CYP3A5*3</i> and <i>CYP3A4*22</i> Cluster Polymorphism Effects on LCP-Tac Tacrolimus Exposure: Population Pharmacokinetic Approach
by: Zeyar Mohammed Ali, et al.
Published: (2023)

Genetic Variation in <i>CYP2D6</i> and <i>SLC22A1</i> Affects Amlodipine Pharmacokinetics and Safety
by: Paula Soria-Chacartegui, et al.
Published: (2023)

Pharmacokinetic Characterization of Supinoxin and Its Physiologically Based Pharmacokinetic Modeling in Rats
by: Yoo-Kyung Song, et al.
Published: (2021)

Investigation of the Impact of <i>CYP3A5</i> Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling
by: Qingfeng He, et al.
Published: (2021)

Application of physiologically based pharmacokinetic modeling in predicting drug–drug interactions for sarpogrelate hydrochloride in humans
by: Min JS, et al.
Published: (2016)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
by: Ioannis Loisios-Konstantinidis, et al.
Published: (2020)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug-Drug Interactions with CYP3A4 Perpetrators
by: Lien Thi Ngo, et al.
Published: (2023)

<i>CYP3A5*3</i> and <i>SLCO1B1</i> c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin
by: Jin-Woo Park, et al.
Published: (2022)

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles
by: Chung H, et al.
Published: (2015)

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects
by: Kim YK, et al.
Published: (2018)

Population Pharmacokinetic Analysis of Tiropramide in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2020)

Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects
by: Seung-Hyun Jeong, et al.
Published: (2021)

Tramadol Steady-State Pharmacokinetics of Immediate-Release Capsules and Sustained-Release Tablets in Dogs
by: Esther Winter, et al.
Published: (2022)

Effect of tramadol on metamizol pharmacokinetics and pharmacodynamics after single and repeated administrations in arthritic rats
by: Luis Alfonso Moreno-Rocha, et al.
Published: (2016)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
by: Thomas Wendl, et al.
Published: (2022)

Physiologically based pharmacokinetic (PBPK) modeling of the role of CYP2D6 polymorphism for metabolic phenotyping with dextromethorphan
by: Jan Grzegorzewski, et al.
Published: (2022)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene-Drug-Drug Interactions
by: Flavia Storelli, et al.
Published: (2019)

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of SA001 and Its Active Metabolite Rebamipide after Single and Multiple Oral Administration
by: Sungyeun Bae, et al.
Published: (2023)

Physiologic and Pharmacokinetic Changes in Pregnancy
by: Maged eCostantine
Published: (2014)

Risk Associated with the <i>LEPR</i> rs8179183 GG Genotype in a Female Korean Population with Obesity
by: Kyunghye Jang, et al.
Published: (2020)

Unravelling bisphenol A pharmacokinetics using physiologically based pharmacokinetic modeling
by: Xiaoxia eYang, et al.
Published: (2015)

Prediction of Pharmacokinetics of IDP-73152 in Humans Using Physiologically-Based Pharmacokinetics
by: Myongjae Lee, et al.
Published: (2022)